ICompany · Healthtech & Bio
Inbiomotion
Inbiomotion is a Barcelona-based precision oncology diagnostics company that spun off from IRB Barcelona and ICREA in 2011. It developed the MAF Test®, a companion diagnostic biomarker test that identifies which early breast cancer patients are likely to benefit from adjuvant bisphosphonate therapy. The MAF Test® is now commercially available, with distribution agreements in South Korea, Sub-Saharan Africa, and Italy.
Founded
2011
Founders
1
News
8
Rounds
1
Investors
5
SectorsPrecision Oncology, Diagnostics, Companion Diagnostics, Biotech
Start-up MapHealthtech & Bio › Diagnostics & precision medicine testing
Profile updated 23 Jul 2026
Founders
R
Roger Gomis
Founder & Chief Scientific Officer
Global models 5
GGRAIL
United States · grail.com ↗
Molecular diagnostics company using genomic biomarkers for early cancer detection, the same biomarker-driven precision oncology model as Inbiomotion's MAF Test.
$2BComparable
FFreenome
United States · www.freenome.com ↗
Develops blood-based biomarker tests to guide cancer screening and treatment decisions, mirroring Inbiomotion's biomarker diagnostic approach.
$1.1BComparable
GGuardant Health
United States · guardanthealth.com ↗
Liquid biopsy company providing molecular biomarker tests that guide oncology treatment decisions, the same companion-diagnostic model.
$550MComparable
NNatera
United States · www.natera.com ↗
Genetic and molecular diagnostics company offering biomarker-based tests used to personalize cancer treatment, similar to Inbiomotion's precision medicine model.
$152MComparable
FFoundation Medicine
United States · www.foundationmedicine.com ↗
Genomic profiling company whose tests stratify cancer patients by biomarker status to guide treatment, directly comparable to Inbiomotion's MAF Test approach.
$96.5MComparable
